

ATTENTION: BOX SEQUENCE

PATENT

Customer No. 22,852

Attorney Docket No. 08647.0001-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Joseph STEINER *et al.*

Application No.: 09/873,298

Filed: June 5, 2001

For: ROTAMASE ENZYME
ACTIVITY INHIBITORS

Group Art Unit: 1627

Examiner: Bennett M. Celsa

HAND CARRY

Commissioner for Patents
Washington, DC 20231

Sir:

**SUBMISSION OF SUBSTITUTE
SEQUENCE LISTING**

Applicants enclose both a paper and a computer-readable copy of a substitute Sequence Listing, which corrects a clerical error in the entry for numeric identifier <213>. In connection with the Sequence Listing submitted concurrently herewith, the undersigned states that:

1. The content of the attached paper copy and the attached computer readable form of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;

2. The Sequence Listing does not add new matter; and

2. All statements made herein of his own knowledge are true and that all

statements made on information and belief are believed to be true; and further; that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


12/3
10-10-02

Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 25, 2002

By: 
William L. Strauss
Reg. No. 47,114

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com